Proxima News and Activities

Proxima is owned by Sumitomo Chemical.

Sumitomo Chemical is one of the...

• Forbes Global 2000 (#1659);
• Nikkei 225;
• TOB Iconic 10,000;
• Topix.

Sumitomo Chemical is a company listed under the stock ticker 4005 (JP).

Sumitomo Chemical has a direct presence in 6 countries.

Sumitomo Chemical has 20 subsidiaries including Aetion, Aramis Biosciences and Asahi Chemical.

They are in:

• Biotechnology52%
• Chemicals24%
• Other24%

Acquisition, funding and merger involving Sumitomo Chemical.

• Proxima has just announced a $80 Million fundraising (posted on January 15 2026).

View the org chart displaying its 21 main executives

Most searched biographies at Proxima

• Zachary Carpenter, Chief Executive Officer
• Meiling Thompson, Chief of Staff
• Michael Bronstein, Chief Scientist in Residence

Popular executive movements at Proxima

• John Cuozzo, Senior Vice President and Head of Drug Discovery, has left the company  (posted on November 3 2025).

Create your alert
to follow the executive moves at Proxima.

Sumitomo Chemical has 2,425 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Chemomab and Scipher Medicine have announced they will merge  (posted on July 13 2026)..
• Apnimed has filed its IPO. Its stock ticker will be APMD. (posted on July 13 2026).
• The new name of EG 427 is Cyllene Therapeutics. (posted on July 10 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Proxima

• Proxima Appoints Dr. Raymond Deshaies, Dr. Lyn Jones, and Dr. Juri Rappsilber to Scientific Advisory Board
• Proxima Raises $80 Million Led by DCVC to Power the Next Generation of Proximity-Based Medicines
• https://proximabio.com/news
• VantAI and Halda Therapeutics Forge Alliance to Discover Next-Generation RIPTAC Medicines
• VantAI Expands Strategic Collaboration with Blueprint Medicines to Advance Induced Proximity Drug Discovery
• VantAI Launches Neo-1, the First AI Model to Rewire Molecular Interactions by Unifying Structure Prediction and Generation for Therapeutic Design
• View more press releases Close

Social media about Proxima

• Proxima on Wikipedia, Google News & Yahoo Finance
• Proxima on LinkedIn, X (Twitter) & YouTube